ArticleScientific reports2025
Ruthenium and recurrent pregnancy loss: insights into oxidative and genotoxic effects.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recurrent pregnancy loss (RPL) remains a complex reproductive challenge, often linked to oxidative stress (OS) and DNA damage. Emerging evidence indicates that rare earth elements, including ruthenium (Ru), may disrupt cellular redox balance and impair genomic stability, thereby posing a potential reproductive risk. This study aimed to investigate whether elevated serum Ru levels are associated with OS and DNA damage in individuals experiencing RPL. A case–control study was conducted involving women with a history of RPL (n = 30) and healthy pregnant controls (n = 30). OS was assessed by quantifying malondialdehyde (MDA) and glutathione (GSH), while DNA damage was evaluated using 8-hydroxy-2′-deoxyguanosine (8-OHdG) levels. Serum Ru was quantified by Inductively Coupled Plasma Mass Spectrometer. The association between Ru and oxidative/DNA damage markers in both groups was evaluated by Pearson correlation analysis. Serum MDA levels were higher in the RPL group (6.08 ± 0.52 nmol/ml) relative to controls (3.36 ± 0.43 nmol/ml, P < 0.001), while GSH levels were reduced (7.43 ± 0.97 mg/ml as opposed to 8.84 ± 0.61 mg/ml, P < 0.001). Similarly, 8-OHdG concentrations were elevated in RPL (23.90 ± 8.64 ng/ml) versus controls (10.12 ± 3.53 ng/ml, P < 0.001). Serum Ru levels were also significantly increased in RPL women (0.002 ± 0.0001 ppb) as against controls (0.001 ± 0.0001 ppb, P < 0.001). Correlation analysis revealed that in the RPL group, Ru was positively associated with MDA (r = 0.47, P < 0.01) and 8-OHdG (r = 0.47, P < 0.01) and negatively with GSH (r = − 0.8, P < 0.001). In contrast, no significant correlations were observed in controls (MDA: r = 0.17, P = 0.35; GSH: r = 0.05, P = 0.75; 8-OHdG: r = 0.32, P = 0.07). Scatter plots further demonstrated positive trends of Ru with MDA and 8-OHdG, and an inverse association with GSH in RPL women. After adjusting for age, BMI, and parity, serum Ru remained a significant independent predictor of OS and DNA damage in women with RPL. Ru was positively associated with MDA (β = +0.18, 95% CI: 0.10–0.26, P < 0.001) and 8-OHdG (β = +0.72, 95% CI: 0.41–1.03, P < 0.001), and inversely with GSH (β = − 0.60, 95% CI: − 0.62 − 0.90, P < 0.001), explaining 38–63% of the variance. This study demonstrates that women with RPL exhibit elevated serum ruthenium levels, which are strongly associated with enhanced OS, reduced antioxidant defense, and increased DNA damage. The positive correlations of Ru with MDA and 8-OHdG, alongside its inverse association with GSH, underscore its potential role as a contributing factor in RPL pathophysiology. These findings highlight Ru as an independent predictor of oxidative imbalance and genomic instability in RPL, suggesting that monitoring environmental or therapeutic Ru exposure may be critical for reproductive health. Further large-scale studies are warranted to confirm these associations and clarify underlying mechanisms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.